Novartis ADR Aktie News

Basel, November 25, 2025 – Novartis will present data from over 70 abstracts, including investigator-initiated trials at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition and 2025 San Antonio Breast Cancer Symposium® (SABCS). Featured among these latest advances in hematology and oncology are 11 oral presentations, with the Phase III VAYHIT2 trial for ianalumab in immune...

The only gene replacement therapy for children two years and older, teens, and adults with spinal muscular atrophy (SMA). The only gene replacement therapy for children two years and older, teens, and adults with spinal muscular atrophy (SMA).

U.S. Food and Drug Administration has approved Novartis' gene therapy for a type of rare muscle disorder, the drugmaker said on Monday.

Ad hoc announcement pursuant to Art. 53 LR Itvisma (onasemnogene abeparvovec-brve) demonstrated improved motor function and stabilization in patients regardless of SMA treatment history in Phase III studies One-time dose of Itvisma replaces SMN1 gene, potentially reducing the need for chronic SMA treatment Gene replacement therapy now available to eligible people of all ages living with SMA Bas...

Novartis AG ( NVS ) Shareholder/Analyst Call November 20, 2025 4:15 AM EST Company Participants Victor Bulto - President of US Angelika Jahreis - Global Head of Development Unit Immunology, Hepatology & Dermatology Richard Siegel Ingrid Zhang Patrick Horber - President of International Dianne Auclair Rocha Ruchira Glaser Shaun Coughlin Shreeram Aradhye - President of Development & Chief Medical...

Novartis AG ( NVS ) Shareholder/Analyst Call November 20, 2025 3:00 AM EST Company Participants Sloan Simpson - Global Head of Investor Relations Vasant Narasimhan - Chief Executive Officer Conference Call Participants Sachin Jain - BofA Securities, Research Division Simon Baker - Rothschild & Co Redburn, Research Division Matthew Weston - UBS Investment Bank, Research Division Steve Scala - TD...

The pharma giant said it is well positioned beyond the decade, citing higher expectations for key drugs.

Switzerland's Novartis on Thursday projected currency-adjusted sales growth of 5% to 6% until 2030 for the group, underpinned by higher peak revenue expectations for its drugs Kisqali and Scemblix.